The governor and state Legislature laid out a plan as part of the budget package in April to cope with any potential shortfalls resulting from a dramatic
decrease in federal funds.
Thanks to
a decrease in federal funding, staff with the drug court program will be out of a job March 31 — meaning the future of the program they provide to recovering addicts is in jeopardy.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth
in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures
in European countries that may increase the amount of discount required on Gilead's products; an increase
in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift
in payer mix to more highly discounted payer segments and geographic regions and
decreases in treatment duration; availability of
funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations
in ADAP purchases driven by
federal and state grant cycles which may not mirror patient demand and may cause fluctuations
in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials
in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations
in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates
in the timelines currently anticipated; Gilead's ability to receive regulatory approvals
in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta
in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes
in its stock price, corporate or other market conditions; fluctuations
in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time
in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
The exit would be preceded by a gradual
decrease in the size of asset purchases (i.e., a slowing
in the amount of extra easing), followed by the end of asset purchases, a gradual withdrawal of excess liquidity from the system, measured increases
in the
federal funds rate and, eventually, a normalization of the Fed's balance sheet.
The press release claimed, «For the first time
in over a decade,
funding needed to sustain the
federal government has
decreased.
The Fed can increase or
decrease the amount of liquidity
in the U.S. financial system by raising or lowering the
federal funds rate.
Under provisions of the current continuing resolution,
federal research
funding would total $ 55.2 billion for FY 2007, a 2.6 percent
decrease that would mark the first year - to - year decline
in at least three decades.
The Center on Education Policy surveyed districts
in the spring and found that 46 percent expect
funding decreases of 5 percent or more
in the 2011 — 12 school year (the poll asked districts about their «total
funds available» for the year, excluding
federal stimulus monies).
While this didn't mean that schools received no
funding, the extreme
decrease in state and
federal funding, (as well as later freezes and sequestrations as the legislature attempted to deal with the state budget), meant that Kentucky's school districts were forced to rely on their other source of income: property taxes.
Given the fiscal priorities of the Trump administration, however, state and local education officials will likely experience
decreases in education spending and grant
funding at the
federal level.
I differ on this point as to the weight of its contributing impact, because this one - time
decrease in state
funding for public education doesn't alter the fact that for the past 20 years
in Texas, total annual public education
funding from all sources — local, state, and
federal — has increased by almost twice the sum of inflation and enrollment growth over that period, even after an adjustment for the growth
in special education students.
Deep cuts to the budget were needed
in order to rebuild the financial reserve to the state minimum, account for increasing expenses such as pensions, and prepare for flat or
decreasing federal and state
funding.
Montana could face a
decrease in federal education
funding as a penalty for that decision.
The first came
in the form of a
decreased discount rate and
federal funds rate.
The disadvantage of bond
funds in general right now is their low rate of return and the fact that once the
Federal Reserve starts to increase interest rates bond
funds typically
decrease in value.
Recent evidence suggests that the
Federal Reserve's monetary policy stance, as gauged by changes in its policy stance (i.e., an increased or decreased target for the federal funds rate), provides useful information that can be effectively used to improve the allocation de
Federal Reserve's monetary policy stance, as gauged by changes
in its policy stance (i.e., an increased or
decreased target for the
federal funds rate), provides useful information that can be effectively used to improve the allocation de
federal funds rate), provides useful information that can be effectively used to improve the allocation decision.